Published in PLoS One on October 24, 2013
The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010. PLoS One (2015) 1.79
Prevalence of Marijuana Use among University Students in Bolivia, Colombia, Ecuador, and Peru. Int J Environ Res Public Health (2015) 1.32
Early Cannabis Use, Polygenic Risk Score for Schizophrenia and Brain Maturation in Adolescence. JAMA Psychiatry (2015) 1.32
Systematic review of general burden of disease studies using disability-adjusted life years. Popul Health Metr (2012) 1.14
A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population--a meta-analysis of 31 studies. BMC Psychiatry (2014) 1.01
Crude estimates of cannabis-attributable mortality and morbidity in Canada-implications for public health focused intervention priorities. J Public Health (Oxf) (2015) 0.91
Building smart cannabis policy from the science up. Int J Drug Policy (2017) 0.90
A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. Neurosci Biobehav Rev (2016) 0.87
Medical marijuana programs - Why might they matter for public health and why should we better understand their impacts? Prev Med Rep (2015) 0.80
Substance use in older HIV-infected patients. Curr Opin HIV AIDS (2014) 0.79
Cannabis Epidemiology: A Selective Review. Curr Pharm Des (2016) 0.79
The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal. Neuropsychopharmacology (2017) 0.79
The effects of prenatal cannabis exposure on fetal development and pregnancy outcomes: a protocol. BMJ Open (2015) 0.77
Cannabis Abuse Is Increasing and Associated with Increased Emergency Department Utilization in Gastroenterology Patients. Dig Dis Sci (2016) 0.76
A pilot study of an online universal school-based intervention to prevent alcohol and cannabis use in the UK. BMJ Open (2014) 0.76
The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil (2017) 0.76
Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia. Eur Arch Psychiatry Clin Neurosci (2015) 0.75
Recruitment, Follow-Up and Characteristics of HIV Infected Adults who Use Illicit Drugs in Southern Africa. J Drug Abuse (2015) 0.75
A clinical comparison of schizophrenia with and without pre-onset cannabis use disorder: a retrospective cohort study using categorical and dimensional approaches. Ann Gen Psychiatry (2015) 0.75
Correction: The Global Epidemiology and Contribution of Cannabis Use and Dependence to the Global Burden of Disease: Results from the GBD 2010 Study. PLoS One (2016) 0.75
Marijuana use and inpatient outcomes among hospitalized patients: analysis of the nationwide inpatient sample database. Cancer Med (2016) 0.75
Readiness to change is a predictor of reduced substance use involvement: findings from a randomized controlled trial of patients attending South African emergency departments. BMC Psychiatry (2016) 0.75
Cannabis-related hippocampal volumetric abnormalities specific to subregions in dependent users. Psychopharmacology (Berl) (2017) 0.75
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA (2000) 55.37
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet (2006) 37.83
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med (2009) 35.37
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (2007) 20.57
No health without mental health. Lancet (2007) 15.22
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet (2012) 11.32
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet (2007) 11.27
A systematic review of the prevalence of schizophrenia. PLoS Med (2005) 6.99
Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet (2012) 6.36
Adverse health effects of non-medical cannabis use. Lancet (2009) 6.25
Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry (2004) 5.95
A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Popul Health Metr (2003) 4.64
Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med (2006) 3.16
Is cannabis use a contributory cause of psychosis? Can J Psychiatry (2006) 2.42
Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales. Addiction (2007) 2.20
Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry (2011) 2.04
Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry (2010) 1.60
New disability weights for the global burden of disease. Bull World Health Organ (2010) 1.59
Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders. Cochrane Database Syst Rev (2007) 1.59
Prevalence and correlates of cannabis use in developed and developing countries. Curr Opin Psychiatry (2007) 1.59
Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry (2008) 1.53
Cannabis use and psychosis. Drug Alcohol Rev (1998) 1.50
Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend (2003) 1.49
What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. Drug Alcohol Depend (2011) 1.43
Gene-environment interplay between cannabis and psychosis. Schizophr Bull (2008) 1.34
What are the policy implications of the evidence on cannabis and psychosis? Can J Psychiatry (2006) 1.31
Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust N Z J Psychiatry (2000) 1.26
Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug Alcohol Rev (2010) 1.24
Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry (2005) 1.24
Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. Cochrane Database Syst Rev (2006) 1.20
Systematic review of prospective studies investigating "remission" from amphetamine, cannabis, cocaine or opioid dependence. Addict Behav (2010) 1.12
Neurobiology of marijuana abuse. Trends Pharmacol Sci (1992) 1.11
Should burden of disease estimates include cannabis use as a risk factor for psychosis? PLoS Med (2009) 0.94
Changing incidence of psychotic disorders among the young in Zurich. Schizophr Res (2007) 0.85
Health states for schizophrenia and bipolar disorder within the Global Burden of Disease 2010 Study. Popul Health Metr (2012) 0.81
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet (2013) 16.76
Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology (2013) 12.46
Neonatal, postneonatal, childhood, and under-5 mortality for 187 countries, 1970-2010: a systematic analysis of progress towards Millennium Development Goal 4. Lancet (2010) 12.28
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet (2012) 11.32
The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA (2013) 10.43
GBD 2010: design, definitions, and metrics. Lancet (2012) 8.64
Healthy life expectancy for 187 countries, 1990-2010: a systematic analysis for the Global Burden Disease Study 2010. Lancet (2012) 8.22
Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet (2013) 7.70
A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry (2007) 7.49
Global patterns of mortality in young people: a systematic analysis of population health data. Lancet (2009) 7.05
A systematic review of the prevalence of schizophrenia. PLoS Med (2005) 6.99
UK health performance: findings of the Global Burden of Disease Study 2010. Lancet (2013) 6.11
Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med (2013) 6.04
Global sodium consumption and death from cardiovascular causes. N Engl J Med (2014) 5.83
The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis (2014) 5.19
Opioid overdose deaths can occur in patients with naltrexone implants. Med J Aust (2007) 4.86
A systematic review of the global prevalence of low back pain. Arthritis Rheum (2012) 4.64
A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Popul Health Metr (2003) 4.64
The long-term health consequences of child physical abuse, emotional abuse, and neglect: a systematic review and meta-analysis. PLoS Med (2012) 4.37
Exploring conditions under which it may be ethical to offer incentives to encourage drug-using women to use long-acting forms of contraception. Addiction (2012) 3.99
Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study. Lancet (2007) 3.97
Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med (2017) 3.90
Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet (2013) 3.65
Cost-effectiveness of interventions to reduce dietary salt intake. Heart (2010) 3.51
The demise of a planned randomised controlled trial in an urban Aboriginal medical service. Med J Aust (2002) 3.41
Affective and anxiety disorders: prevalence, treatment and antidepressant medication use. Aust N Z J Psychiatry (2010) 3.26
Population Health Metrics Research Consortium gold standard verbal autopsy validation study: design, implementation, and development of analysis datasets. Popul Health Metr (2011) 3.21
Robust metrics for assessing the performance of different verbal autopsy cause assignment methods in validation studies. Popul Health Metr (2011) 3.10
Global burden of disease 2005: call for collaborators. Lancet (2007) 2.64
Burden of disease and injury in Australia in the new millennium: measuring health loss from diseases, injuries and risk factors. Med J Aust (2008) 2.63
Performance of physician-certified verbal autopsies: multisite validation study using clinical diagnostic gold standards. Popul Health Metr (2011) 2.62
The long-term effectiveness of brief interventions for unsafe alcohol consumption: a 10-year follow-up. Addiction (2002) 2.61
Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide. BMJ Open (2013) 2.40
Using verbal autopsy to measure causes of death: the comparative performance of existing methods. BMC Med (2014) 2.39
Performance of the Tariff Method: validation of a simple additive algorithm for analysis of verbal autopsies. Popul Health Metr (2011) 2.32
Reductions in child mortality levels and inequalities in Thailand: analysis of two censuses. Lancet (2007) 2.30
Should the health community promote smokeless tobacco (snus) as a harm reduction measure? PLoS Med (2007) 2.10
Trends in disease burden in Germany: results, implications and limitations of the Global Burden of Disease study. Dtsch Arztebl Int (2014) 2.09
Performance of InterVA for assigning causes of death to verbal autopsies: multisite validation study using clinical diagnostic gold standards. Popul Health Metr (2011) 2.06
Meta-analysis of prevalence. J Epidemiol Community Health (2013) 2.03
Cost-effectiveness of interventions to prevent alcohol-related disease and injury in Australia. Addiction (2009) 2.01
Stimulant use and stimulant use disorders in Australia: findings from the National Survey of Mental Health and Wellbeing. Med J Aust (2011) 2.00
Cognitive behavioural therapy for depression, panic disorder and generalized anxiety disorder: a meta-regression of factors that may predict outcome. Aust N Z J Psychiatry (2006) 1.98
A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. Schizophr Bull (2003) 1.88
Mortality in Iraq associated with the 2003-2011 war and occupation: findings from a national cluster sample survey by the university collaborative Iraq Mortality Study. PLoS Med (2013) 1.86
Patterns of antipsychotic medication use in Australia 2002-2007. Aust N Z J Psychiatry (2010) 1.86
Lifetime prevalence estimates of major depression: an indirect estimation method and a quantification of recall bias. Eur J Epidemiol (2005) 1.86
The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction (2012) 1.83
Excess Indigenous mortality: are Indigenous Australians more severely disadvantaged than other Indigenous populations? Int J Epidemiol (2007) 1.78
GBD 2010: a multi-investigator collaboration for global comparative descriptive epidemiology. Lancet (2012) 1.77
The prevalence of psychological distress in employees and associated occupational risk factors. J Occup Environ Med (2008) 1.76
Estimated causes of death in Thailand, 2005: implications for health policy. Popul Health Metr (2010) 1.74
The burden of disease in Zimbabwe in 1997 as measured by disability-adjusted life years lost. Trop Med Int Health (2006) 1.72
Measuring the global burden of low back pain. Best Pract Res Clin Rheumatol (2010) 1.71
Psychotic-like experiences in major depression and anxiety disorders: a population-based survey in young adults. Schizophr Bull (2009) 1.65